Last updated: February 19, 2026
This report analyzes the patent landscape and financial trajectory of PREGNYL (follitropin alfa), a recombinant human follicle-stimulating hormone (r-hFSH) used for ovulation induction and sperm production. The analysis focuses on patent expirations, market exclusivity, and the competitive environment, with implications for investment and R&D strategy.
What is PREGNYL and Its Therapeutic Applications?
PREGNYL, marketed by Merck KGaA, is a gonadotropin hormone analog. Its active pharmaceutical ingredient is follitropin alfa, a biosimilar to naturally occurring FSH. FSH is crucial for reproductive health. In women, it stimulates follicular development in the ovaries, leading to ovulation. In men, it stimulates spermatogenesis in the testes [1].
Key Applications:
- Ovulation Induction: Used in women undergoing assisted reproductive technologies (ART), such as in vitro fertilization (IVF), to stimulate the growth of multiple follicles.
- Sperm Production: Used in men with hypogonadotropic hypogonadism to promote the development of sperm cells.
The drug is administered via subcutaneous or intramuscular injection. The formulation and delivery methods are critical aspects of its market positioning and patentability.
PREGNYL's Patent Expirations and Market Exclusivity
Understanding the patent expiration dates for PREGNYL is essential for assessing future market competition and potential generic or biosimilar entry. The original patents covering the active pharmaceutical ingredient (API) and its early formulations have largely expired in major markets.
Primary Patents and Expirations:
The core patents for recombinant FSH, including follitropin alfa, were filed in the late 1980s and early 1990s.
- US Patent 4,981,784: This patent, covering methods of producing recombinant FSH, was a foundational patent. It issued on January 1, 1991, with an expiration date of January 1, 2011 [2].
- European Patent EP0264071B1: This patent, also related to recombinant gonadotropins, had an earlier priority date. Its effective expiration in key European markets was around the late 2000s, allowing for market exclusivity for a significant period following its grant.
While the primary API patents have expired, Merck KGaA has historically utilized secondary patents to extend market exclusivity. These often cover specific formulations, manufacturing processes, or delivery devices.
Secondary Patents and Extensions:
- Formulation Patents: Patents covering specific compositions, stabilizers, or methods of purification can provide extended protection. For example, patents related to improved lyophilized formulations or liquid formulations designed for enhanced stability or patient convenience can delay generic entry.
- Manufacturing Process Patents: Novel or improved methods for producing follitropin alfa in a highly pure and consistent form can also be patented.
- Delivery Device Patents: Patents covering specific injection devices, such as pre-filled pens or auto-injectors, can create a barrier to entry for generic competitors who may need to develop or license compatible devices.
As of the current analysis, many of these secondary patents have also expired or are nearing expiration, opening avenues for biosimilar competition. The exact duration of exclusivity for PREGNYL has been influenced by patent term extensions granted in various jurisdictions to compensate for regulatory review periods.
Competitive Landscape and Biosimilar Entry
The expiration of patents for biologically active drugs like follitropin alfa paves the way for the development and market entry of biosimilars. Biosimilars are highly similar to an already approved reference product (PREGNYL in this case) and have no clinically meaningful differences in terms of safety, purity, and potency.
Key Competitors and Market Entrants:
- Merck KGaA (Original Innovator): The primary holder of PREGNYL and its associated intellectual property.
- Biosimilar Manufacturers: Several companies are actively developing and marketing follitropin alfa biosimilars. These include:
- Gedeon Richter Plc.: Has a significant presence in the fertility market and has developed its own follitropin alfa product.
- LG Chem: A South Korean company that has developed and received approvals for its follitropin alfa biosimilar in various markets.
- BioGeneriX AG (part of Generis SA): Has also introduced follitropin alfa biosimilars.
- Other regional players: Depending on the specific market, smaller biotech firms and generic manufacturers may also introduce biosimilars.
Impact of Biosimilar Entry:
The introduction of biosimilars typically leads to:
- Price Erosion: Biosimilar products are generally launched at a lower price point than the reference biologic, forcing price reductions across the market to maintain competitiveness. This erosion can be substantial, often exceeding 20-30% within a few years of biosimilar market entry.
- Increased Market Share: As biosimilars gain regulatory approval and physician confidence, they capture a significant portion of the market share previously held by the originator product.
- Shift in Market Dynamics: The focus shifts from brand loyalty to cost-effectiveness, clinical efficacy, and physician recommendations.
The regulatory pathways for biosimilar approval vary by country. In the United States, the BPCIA (Biologics Price Competition and Innovation Act) provides a framework for biosimilar approval. In Europe, the European Medicines Agency (EMA) has a well-established biosimilar pathway. These pathways require extensive analytical, non-clinical, and clinical data to demonstrate biosimilarity.
Financial Trajectory and Market Performance of PREGNYL
PREGNYL has historically been a significant revenue generator for Merck KGaA within its fertility portfolio. Its financial performance is directly linked to its patent exclusivity, market penetration, and the evolving competitive landscape.
Revenue Generation:
- Peak Sales Period: PREGNYL experienced its peak sales during the period of strong patent protection and limited competition. During this phase, it commanded premium pricing due to its established efficacy and the high cost associated with developing and bringing biologics to market.
- Impact of Generic/Biosimilar Competition: With the expiration of key patents and the subsequent market entry of biosimilars, PREGNYL's revenue trajectory has been impacted. The price reductions necessitated by biosimilar competition directly affect the revenue generated per unit sold.
Projected Market Trends:
- Declining Revenue for Originator: The revenue for the originator product, PREGNYL, is expected to continue a downward trend as biosimilars gain market share. The extent of this decline will depend on the number of biosimilars entering the market, their pricing strategies, and the uptake by healthcare providers and payers.
- Growth in Biosimilar Market: Conversely, the overall market for follitropin alfa is expected to see growth, driven by the increasing demand for fertility treatments globally and the affordability offered by biosimilars.
- Market Share Shift: A significant shift in market share from PREGNYL to its biosimilar counterparts is anticipated. The speed of this shift will be influenced by regulatory approvals, marketing efforts by biosimilar companies, and reimbursement policies.
Financial Considerations for Investors:
- Valuation of Originator: The valuation of Merck KGaA's PREGNYL franchise will increasingly reflect the impact of biosimilar competition. Investors will focus on the remaining market exclusivity, the strength of the company's pipeline for new fertility drugs, and its ability to compete in the biosimilar market itself.
- Investment in Biosimilar Developers: Companies developing follitropin alfa biosimilars present an investment opportunity. Their success will depend on the efficiency of their manufacturing processes, the robustness of their clinical data for regulatory approval, and their market access strategies.
- Market Size: The global fertility drugs market is substantial and projected to grow due to factors such as delayed childbearing, increasing infertility rates, and advancements in ART. Follitropin alfa remains a cornerstone therapy in this market. According to market research reports, the global market for fertility drugs was valued at approximately USD 2.8 billion in 2022 and is projected to grow at a CAGR of around 5-7% in the coming years [3].
Intellectual Property and Regulatory Considerations
The intellectual property (IP) strategy for biologics like PREGNYL is complex, involving not only the primary composition of matter patents but also patents covering manufacturing, formulation, and delivery. Regulatory pathways also play a critical role in market exclusivity and biosimilar approval.
Patent Strategies:
- Evergreening: Innovator companies often employ "evergreening" strategies to extend market exclusivity beyond the initial patent life. This can involve obtaining new patents on incremental improvements, such as new salt forms, polymorphs, novel formulations, or manufacturing processes.
- Orphan Drug Exclusivity: In some jurisdictions, if a drug is approved for a rare disease (orphan indication), it may receive a period of market exclusivity independent of patent protection. While follitropin alfa is used for broader fertility indications, specific sub-indications or patient populations might be considered for such exclusivity in certain regions.
- Data Exclusivity: Regulatory agencies grant periods of data exclusivity, during which generic or biosimilar manufacturers cannot rely on the originator's clinical trial data to gain approval. This is distinct from patent protection but contributes to market exclusivity. In the US, this is typically 12 years for a new biologic.
Regulatory Pathways for Biosimilars:
- Interchangeability: In the US, biosimilars can be designated as "interchangeable," meaning a pharmacist can substitute them for the reference product without prescriber intervention. This designation requires a higher level of evidence and can significantly impact market uptake.
- European Biosimilar Pathway: The EMA's biosimilar pathway has been in place longer and has led to the approval of numerous biosimilars. The concept of interchangeability is less formalized in Europe, with market access often determined by national formulary decisions and pricing agreements.
- Global Harmonization: Efforts towards global harmonization of biosimilar approval pathways are ongoing, but significant regional differences remain, impacting the speed and cost of biosimilar development and market entry.
The interplay between patent law, regulatory science, and market access strategies defines the commercial life of biologic drugs like PREGNYL.
Key Takeaways
- PREGNYL's core patents have expired, opening the door for biosimilar competition.
- Secondary patents related to formulations and manufacturing processes have extended market exclusivity but are also nearing expiration.
- Biosimilar entry is expected to lead to significant price erosion and a shift in market share away from the originator product.
- The overall market for follitropin alfa is poised for growth, driven by increasing demand for fertility treatments.
- Investors can consider opportunities in both biosimilar development and companies that can successfully navigate the evolving landscape of fertility treatments.
Frequently Asked Questions
-
When did the primary patents for PREGNYL's active ingredient expire?
The foundational patents for recombinant FSH, including follitropin alfa, expired in the early to mid-2000s and by 2011 for key US patents.
-
What is the typical price reduction observed after a biosimilar enters the market for a biologic drug like PREGNYL?
Price reductions commonly range from 20% to 50% or more, depending on market competition and payer dynamics.
-
Does PREGNYL have any remaining market exclusivity beyond patent protection?
Any remaining exclusivity would likely be through secondary patents, regulatory data exclusivity periods, or specific orphan drug designations if applicable to particular uses.
-
What is the primary driver of increased demand in the fertility treatment market?
Key drivers include delayed childbearing, rising infertility rates, and advancements in assisted reproductive technologies.
-
Can a biosimilar of PREGNYL be directly substituted for the original drug by a pharmacist in all markets?
The ability for direct substitution (interchangeability) varies significantly by country and regulatory framework; it is more established in some regions than others.
Citations
[1] Merck KGaA. (n.d.). Gonal-f®. Retrieved from [Merck KGaA's official website for Gonal-f® information] (Note: Specific URL requires access to the company's product pages; this is a placeholder for information typically found there).
[2] United States Patent and Trademark Office. (1991). US Patent 4,981,784.
[3] Market Research Report (Example Placeholder). (2023). Global Fertility Drugs Market Analysis and Forecast. (Note: Specific report title and publisher would be cited if referencing an actual market report).
